Source disclosure: February 13, 2026
Medrx Co.,Ltd. [4586.T]
TOKYO, Feb 13 (Pulse News Wire) – Medrx CO.,LTD. (4586.T) reported its fiscal year 2025 fourth quarter earnings, which fell below initial forecasts due to adjustments in research and development expenses.
According to the company's filing, the previous forecast indicated sales of ¥122 million, operating profit of ¥--¥1.335 billion, ordinary profit of ¥--¥1.335 billion, and net income per share of ¥--¥1.350 billion. However, the actual results showed sales of ¥128 million, operating profit of ¥--¥941 million, ordinary profit of ¥--¥937 million, and net income per share of ¥--¥937 million. This resulted in a difference of ¥6¥393 million, representing a decrease of 4.5%.
The discrepancy was attributed to delays in external costs and a reassessment of estimated expenses related to the MRX-4TZT clinical phase II trial, which began on December 24, 2026. As a result, some planned expenses for fiscal year 2025 were deferred to fiscal year 2026, leading to reduced research and development costs. Consequently, the company’s lower operating profit, ordinary loss, and parent company attributable loss decreased by ¥393 million, ¥397 million, and ¥412 million respectively.
AI-translated content. 🟢 Confidence: High See terms • Original filing